


In the Claims:

This listing of claims will replace all prior versions, and listings of the claims in the application.

Please amend claims 1-7 and 10, please cancel claims 8-9 and 11, and please add new claims 12-23 as follows.

1. (Currently amended) A compound in accord with formula I:



I

wherein:

R^1 and R^2 at each occurrence is independently selected from hydrogen, CN, CF_3 , OCF_3 , $OCHF_2$, halogen, C_{1-4} alkyl, C_{2-4} alkenyl, C_{2-4} alkynyl, R^a , R^b , SR^a , NR^aR^b , $CH_2NR^aR^b$, OR^c , or CH_2OR^c , ~~where~~ wherein R^a , R^b , and R^c are independently at each occurrence selected from hydrogen, C_{1-6} alkyl, $C(O)R^d$, $C(O)NHR^d$, CO_2R^d , or R^a and R^b may together be $(CH_2)_jG(CH_2)_k$ or $G(CH_2)_jG$ ~~where~~ wherein G is oxygen, j is 1, 2, 3, or 4, k is 0, 1, or 2; R^d at each occurrence is independently selected from C_{1-6} alkyl;

R^3 is hydrogen or C_{1-4} alkyl;


R^6 is hydrogen, CN, C_{1-4} alkyl or C_{1-4} alkoxy;

R^7 is hydrogen or C_{1-4} alkyl[[,]]₁; and

Ar is phenyl or phenyl substituted at one or two positions with moieties independently selected from R^4 or R^5 ~~where~~ wherein R^4 and R^5 at each occurrence are independently selected from halogen, C_{1-4} alkoxy or halogenated C_{1-4} alkyl;

~~in vivo hydrolysable precursors thereof~~, and pharmaceutically acceptable salts thereof.

2. (Currently amended) A compound according to Claim 1, in accord with formula II:



II

wherein:

R^1 , R^2 , R^3 , R^4 , R^5 , and R^7 are as defined in Claim 1,

~~in vivo hydrolysable precursors thereof, and~~ or a pharmaceutically acceptable salts salt thereof.

3. (Currently amended) A compound according to Claim 1, wherein:

Ar is selected from 4-chlorophenyl, 4-fluorophenyl, 4-methoxyphenyl, 3,4-dichlorophenyl, 3,4-dimethoxyphenyl, or 4-trifluoromethylphenyl[[,]] ;

~~in vivo hydrolysable precursors thereof, and~~ or a pharmaceutically acceptable salts salt thereof.

4. (Currently amended) A compound according to Claim 1, wherein:

R^1 is selected from hydrogen, methoxy or ethyl;

R^2 is selected from hydrogen or methoxy;

R^3 is selected from hydrogen or methyl;

~~in vivo hydrolysable precursors thereof, and~~ or a pharmaceutically acceptable salts salt thereof.

5. (Currently amended) A pharmaceutically-acceptable ~~salts~~ salt of a compound according to Claim 1 made with an inorganic or organic acid which affords a physiologically-acceptable anion.

6. (Currently amended) A pharmaceutically-acceptable ~~salts~~ salt of a compound according to Claim 5, wherein said inorganic or organic acid is selected from hydrochloric, hydrobromic, sulfuric, phosphoric, methanesulfonic, sulfamic, para-toluenesulfonic, acetic, citric, lactic, tartaric, malonic, fumaric, ethanesulfonic, benzenesulfonic, cyclohexylsulfamic, salicylic or quinic acids.

7. (Currently amended) A pharmaceutical composition comprising a compound according to Claim 1, ~~an in vivo hydrolysable precursor or a pharmaceutically acceptable salt thereof~~ and a pharmaceutically-acceptable carrier.

8-9. (Canceled).

10. (Currently amended) A method of treating a disorder or condition selected from ~~hypertension~~, depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression, ~~generalized anxiety disorder, agoraphobia, social phobia, simple phobias, posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, anorexia nervosa, bulimia nervosa, obesity, addictions to alcohol, cocaine, heroin, phenobarbital, nicotine or benzodiazepines; cluster headache, migraine, pain, Alzheimer's disease, obsessive compulsive disorder, panic disorder, dementia, amnestic disorders, age-related cognitive decline, dementia in Parkinson's disease, neuroleptic-induced parkinsonism, tardive dyskinesias, hyperprolactinaemia, vasospasm, cerebral vasculature vasospasm, cerebellar ataxia, gastrointestinal tract disorders, negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity~~

~~disorder, chronic paroxysmal hemicrania or headache associated with vascular disorders in a mammal, wherein antagonism of the NK1 receptors and SSRI activity is beneficial, comprising administering an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, effective in treating such disorder or condition. and a pharmaceutically-acceptable carrier.~~

11. (Canceled).

12. (New) A method for treating depression, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

13. (New) A method for treating generalized anxiety disorder comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 1, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

14. (New) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression in a mammal, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 2, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

15. (New) A method for treating depression, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 2, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

16. (New) A method for treating generalized anxiety disorder, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 2, or a

pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

17. (New) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression in a mammal, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 4, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

18. (New) A method for treating depression, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 4, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

19. (New) A method for treating generalized anxiety disorder, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 4, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

20. (New) A compound according to Claim 1, wherein said compound is selected from:

1-N-Methyl-4-(4-chlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-methoxyphenyl)-4-(3-(3-cyano-2,4-dimethoxynaphth-1-yl)-(2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(3,4-dichlorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-chlorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(2-N-ethyl-2-azaprop-1-yl))piperidine;

1-N-Methyl-4-(4-fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-N-ethyl-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(2,4-dimethoxy-3-cyanonaphth-1-yl)-(2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyanonaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-methoxynaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine;

4-(4-Fluorophenyl)-4-(3-(3-cyano-2-ethylnaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine; and

4-(4-Fluorophenyl)-4-(3-(2,4-dimethoxy-3-cyanonaphth-1-yl)-(2-N-methyl-2-azaprop-1-yl))piperidine.

21. (New) A method for treating a disorder or condition selected from depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, pediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, and post partum depression, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 20, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

22. (New) A method for treating depression, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 20, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.

23. (New) A method for treating generalized anxiety disorder, comprising administering to a warm-blooded animal an effective amount of a compound according to Claim 20, or a pharmaceutically-acceptable salt thereof, and a pharmaceutically-acceptable carrier.